Medolac Laboratories

What Medolac Laboratories does

Medolac Laboratories is a US private Public Benefit Corporation that produces shelf-stable, commercially sterile donor human milk products for premature and at-risk infants. Its core product line consists of Benefit-18, Benefit-20, and Benefit-24 — donor milk standardized to specific caloric targets and formulated for NICU use — together with FortifyMVP, a human milk-based fortifier designed to support an exclusive human milk diet in preterm care. Medolac's core technical differentiator is the use of commercial Retort sterilization combined with pooled-milk pre-screening and homogenization, which eliminates heat-stable spores and pathogens that survive the Holder pasteurization used by conventional milk banks, and yields a commercially sterile, room-temperature-stable product with consistent nutrient composition.

The company operates a dual-channel go-to-market: direct enterprise sales to hospital NICUs across the United States, supported by clinical education and integration into the Keriton Kare feeding management platform; and direct-to-consumer shipment of donor milk to patient homes via prescription for post-discharge supplementation. Donor screening is conducted in partnership with LabCorp, and donor recruitment is handled through MothersMilk.coop, with Medolac operating as the processor and brand owner. The company is a federally registered food facility subject to annual FDA inspections and is licensed as a tissue bank in California, New York, and Maryland.

Medolac is structured as a Public Benefit Corporation, prioritizing mission-driven decision-making over shareholder returns. With 11–50 employees and headquarters listed in Lake Oswego, Oregon (with operations noted in Boulder City, Nevada), the company pursues a research-backed go-to-market that combines peer-reviewed publications, scientific content marketing, and clinical engagement. The addressable market is materially underpenetrated — Medolac cites that only ~10% of US premature infants currently have access to donor milk — leaving significant runway for expansion if commercial execution, reimbursement, and supply scaling keep pace with clinical demand.

Name

Medolac Laboratories

Legal name

Medolac Laboratories

Website

https://medolac.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Medolac Laboratories is a US Public Benefit Corporation that produces shelf-stable, commercially sterile donor human milk products (Benefit-18/20/24 and FortifyMVP fortifier) for premature infants, selling to hospital NICUs via direct enterprise sales and to parents through prescription-based home delivery.

Ownership category

akta.pro rank

Product category

Neonatal Nutrition

NAICS

Dairy Product (except Frozen) Manufacturing (31151)

SIC

Dairy Products (2020)

akta.pro primary industry

Standard Infant Formula Manufacturing (Cow Milk–Based) (AFAHAHAA)

akta.pro secondary industries

Baby Feeding Supplements & Fortifiers (Probiotics, DHA/ARA, Vitamins) (CRADAEAI), Human Milk Fortifier (HMF) Manufacturing (Bovine-Derived) (AFAHAHAI)

Keywords

• Donor human milk
• Human milk fortifier
• Neonatal nutrition
• NICU feeding
• Infant nutrition products

Headquarters

HQ city

Lake Oswego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Donor Human Milk Product Sales: Medolac sells its Benefit donor milk product line (Benefit-18, Benefit-20, Benefit-24) and FortifyMVP human milk-based fortifier to hospitals (primarily NICUs) and directly to parents via prescription. Products are sold in standardized caloric formulations with standardized nutrient composition.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Medolac Laboratories processes and distributes shelf-stable, commercially sterile donor human milk products standardized to specific caloric targets (Benefit-18, Benefit-20, Benefit-24) along with FortifyMVP, a human milk-based fortifier. The products use Retort sterilization and homogenization to deliver room-temperature storage nutrition primarily for premature infants in NICUs and post-discharge use at home.

Product overview

Medolac Laboratories offers a portfolio of shelf-stable, commercially sterile donor human milk products standardized to specific caloric targets. The Benefit product line includes Benefit-18 (18 kcal/oz), Benefit-20 (20 kcal/oz), and Benefit-24 (24 kcal/oz), which is specifically formulated to match preterm milk protein content. All Benefit products are homogenized and use Retort sterilization processing. The FortifyMVP Fortifier is a human milk-based fortifier that supplements the donor milk products to support exclusive human milk feeding in NICU settings.

Differentiator

Problem solved

Functional benefit

Brands

• Benefit-18: Donor milk product with 18 kcal/oz, stored at room temperature, commercially-sterile and homogenized
• Benefit-20
• Benefit-24
• FortifyMVP
• Benefit Nutrition Portfolio

Products and services

• Benefit-18 Donor Milk

Quantifiable outcome

• Donor human milk reduces the risk of NEC by 79%
• +7 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature7 records

Partnerships

Three partnerships are on record, tiered core and supporting.

• Keriton KarecoreTechnology or IntegrationMedolac Benefit human milk-based nutrition product bar codes are integrated into the Keriton Kare feeding management platform. Keriton helps healthcare professionals track neonatal nutrition and enables proper identification and tracking of Medolac donor milk products at the bedside.
• LabCorpsupportingTechnology or IntegrationDonors who meet health history requirements go to a LabCorp near their home to have a blood sample taken to verify no infections are present before being approved to provide milk to Medolac.
• MothersMilk.coopsupportingChannel Partner/ Reseller/ DistributorMedolac directs mothers interested in breast milk donation to visit www.mothersmilk.coop, which handles the donor recruitment and milk collection for Medolac's supply chain.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Prolacta Bioscience: Prolacta is the leading manufacturer of human milk-based fortifiers and nutrition products for premature infants in NICUs. It is the closest direct competitor to Medolac's FortifyMVP and Benefit product lines, targeting the same hospital procurement teams with overlapping value propositions around exclusive human milk diets.
• NiMBALCare: NiMBALCare (formerly NiMBAL) is a human milk nutrition company that provides donor milk-based products to NICUs. It competes directly with Medolac's Benefit line on hospital sales of standardized donor milk for premature infants.
• Mothers' Milk Bank of Northeast: A HMBANA-affiliated non-profit donor milk bank that distributes pasteurized donor milk to NICUs across the northeastern US. It represents the non-profit incumbent channel against which Medolac must compete on safety, convenience, and price.
• The Milk Bank (Indiana): An HMBANA-affiliated non-profit milk bank serving NICUs across the Midwest and beyond. It is one of the larger non-profit donor milk distributors and a direct competitor for hospital donor milk contracts.

Emerging players

• LactaLogics: LactaLogics is an emerging human milk processing company focused on donor milk for neonatal use. It competes with Medolac in NICU donor milk supply with a different processing approach, making it a relevant emerging direct competitor.
• Bobbie: Bobbie is an emerging organic infant formula brand focused on the US market. While primarily a consumer brand rather than a NICU supplier, it represents a new generation of mission-driven infant nutrition companies competing for the same parent customer base as Medolac's DTC channel.
• Biomilq: Biomilq is a biotech company developing cell-cultured human milk components as an alternative to both formula and donor milk. Although pre-commercial, it represents a long-term disruptive threat to Medolac's donor milk business model.

Broad incumbents

• Abbott Nutrition (Similac): Abbott Nutrition manufactures Similac infant formulas including preterm and specialty formulas that compete with Medolac's products in NICU feeding decisions. As a broad incumbent, Abbott has far larger scale, sales infrastructure, and hospital relationships.
• Mead Johnson Nutrition (Reckitt): Mead Johnson, owned by Reckitt, makes Enfamil infant formulas including Enfamil Human Milk Fortifier used in NICUs. It is a broad incumbent competing with both Medolac's donor milk and its FortifyMVP product through established hospital sales networks.
• Nestlé Health Science: Nestlé Health Science offers a portfolio of pediatric and neonatal nutrition products including infant formulas. As a broad incumbent in clinical nutrition, it competes with Medolac for hospital formulary placement in NICU feeding protocols.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/medolac
• Facebookfacebook.com/medolaclabs
• LinkedInlinkedin.com/company/medolac-laboratories

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medolac Laboratories